ATA238582A - Verfahren zur herstellung von neuen prolinderivaten - Google Patents

Verfahren zur herstellung von neuen prolinderivaten

Info

Publication number
ATA238582A
ATA238582A AT0238582A AT238582A ATA238582A AT A238582 A ATA238582 A AT A238582A AT 0238582 A AT0238582 A AT 0238582A AT 238582 A AT238582 A AT 238582A AT A238582 A ATA238582 A AT A238582A
Authority
AT
Austria
Prior art keywords
producing new
prolin
derivatives
prolin derivatives
producing
Prior art date
Application number
AT0238582A
Other languages
English (en)
Other versions
AT390619B (de
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to AT0362883A priority Critical patent/AT386603B/de
Publication of ATA238582A publication Critical patent/ATA238582A/de
Application granted granted Critical
Publication of AT390619B publication Critical patent/AT390619B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01DMEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
    • G01D2205/00Indexing scheme relating to details of means for transferring or converting the output of a sensing member
    • G01D2205/70Position sensors comprising a moving target with particular shapes, e.g. of soft magnetic targets
    • G01D2205/77Specific profiles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT0238582A 1981-06-19 1982-06-21 Verfahren zur herstellung von neuen prolinderivaten AT390619B (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT0362883A AT386603B (de) 1981-06-19 1983-10-11 Verfahren zur herstellung von neuen prolinderivaten

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56094002A JPS57209270A (en) 1981-06-19 1981-06-19 Proline derivative

Publications (2)

Publication Number Publication Date
ATA238582A true ATA238582A (de) 1989-11-15
AT390619B AT390619B (de) 1990-06-11

Family

ID=14098203

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0238582A AT390619B (de) 1981-06-19 1982-06-21 Verfahren zur herstellung von neuen prolinderivaten

Country Status (5)

Country Link
JP (1) JPS57209270A (de)
AT (1) AT390619B (de)
BE (1) BE893553A (de)
SU (1) SU1272982A3 (de)
ZA (1) ZA823779B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2362998T3 (es) 2002-08-19 2011-07-18 Pfizer Inc. Terapia de combinación para enfermedades hiperproliferativas.
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
CN115819270A (zh) * 2021-09-17 2023-03-21 洛阳中科生物芯片技术有限公司 金刚烷胺半抗原、金刚烷胺抗原、制备方法以及金刚烷胺单克隆抗体及金刚烷胺检测试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR73585B (de) * 1978-09-11 1984-03-26 Univ Miami
ZA802420B (en) * 1979-05-18 1981-04-29 Squibb & Sons Inc Aminoacyl derivatives of mercaptoacyl amino acids
PT70158A1 (en) * 1980-03-03 1982-03-01 Univ Miami Process for preparing anti-hypertensive agents

Also Published As

Publication number Publication date
JPS57209270A (en) 1982-12-22
AT390619B (de) 1990-06-11
BE893553A (fr) 1982-12-17
ZA823779B (en) 1984-01-25
JPS6313433B2 (de) 1988-03-25
SU1272982A3 (ru) 1986-11-23

Similar Documents

Publication Publication Date Title
AT377524B (de) Verfahren zur herstellung von neuen anthracyclinglycosiden
AT382612B (de) Verfahren zur herstellung von neuen arylcyclobutylalkylaminen
ATA20485A (de) Verfahren zur herstellung von neuen tetrahydrocarbazol-derivaten
AT378768B (de) Verfahren zur herstellung von neuen 1-sulfo-2-oxoazetidin-derivaten
AT382150B (de) Verfahren zur herstellung von neuen 3-amino-2-oxo-azetidin-1-sulfonsaeurederivaten
AT384017B (de) Verfahren zur herstellung von neuen hydroxyaminoestern
AT381091B (de) Verfahren zur herstellung von neuen ergolinderivaten
AT386199B (de) Verfahren zur herstellung von neuen 2-piperazinopyrimidinen
AT376654B (de) Verfahren zur herstellung von neuen 1-phenyl-2cyclohexen-1-alkylamin-derivaten
AT375943B (de) Verfahren zur herstellung von neuen mitosanverbindungen
ATA404284A (de) Verfahren zur herstellung von neuen gonadoliberin-derivaten
ATA238582A (de) Verfahren zur herstellung von neuen prolinderivaten
AT379388B (de) Verfahren zur herstellung von neuen 4-chinolonderivaten
AT380477B (de) Verfahren zur herstellung von neuen spirothiazolidindion-derivaten
AT376222B (de) Verfahren zur herstellung von neuen azinorifamycinverbindungen
AT375076B (de) Verfahren zur herstellung von neuen ergolinderivaten
AT384214B (de) Verfahren zur herstellung von neuen mercaptoacylcarnitinen
ATA106084A (de) Verfahren zur herstellung von neuen gonadoliberin-derivaten
AT381318B (de) Verfahren zur herstellung von neuen nitrosoharnstoffderivaten
AT377264B (de) Verfahren zur herstellung von neuen nitrosoharnstoffderivaten
ATA284985A (de) Verfahren zur herstellung von neuen carbapenemderivaten
AT373891B (de) Verfahren zur herstellung von neuen rifamycinderivaten
AT374451B (de) Verfahren zur herstellung von neuen benzylidenderivaten
AT381939B (de) Verfahren zur herstellung von neuen azaspiroalkandionen
ATA362883A (de) Verfahren zur herstellung von neuen prolinderivaten

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee